Table 2.

Median and interquartile ranges of inflammatory markers and neutrophil to lymphocyte ratio (NLR) before and after tocilizumab administration.

	Overall (N = 514)			Patients who were discharged (N = 363)			Patients who expired (N = 118)
	Before TCZ	After TCZ	P value*	Before TCZ	After TCZ	P value*	Before TCZ	After TCZ	P value*
NLR	9.6 [7–12.8]	4.3 [1.5–10.6]	0.015	9.5 [6.8–12.6]	3.5 [2.2–7.8]	<0.001	12.9 [9.9–17.5]	10.3 [8.5–15.3]	0.231
CRP	139 [78.2–181]	8.3 [2.11–19.5]	<0.001	140.8 [79.2–182.5]	5.99 [1.75–15.3]	<0.001	124 [71.9–180]	16.9 [5.64–62.0]	<0.001
LDH	548 [438.3–666]	461 [365–605]	<0.001	523 [421–636]	413 [335–513]	<0.001	619 [460.5–736]	673 [520–977.5]	<0.001
Ferritin	1092 [577–1541]	977 [620–1398]	<0.001	1094 [582.3–1525.3]	929 [619–1324]	<0.001	1104 [535–1532.8]	1200 [659–1627.3]	0.1333
D-dimer	1.0 [0.6–2.2]	1.2 [0.6–3.23]	0.723	0.9 [0.5–1.75]	0.9 [0.5–1.8]	0.041	1.55 [0.8–3.3]	3.3 [1.6–6.95]	<0.001
PCT	0.23 [0.12–0.44]	0.65 [0.13–5.2]	<0.001	0.22 [0.11–0.40]	1.57 [0.11–5.68]	<0.001	0.25 [0.15–0.51]	0.59 [0.22–3.58]	<0.001

NLR: Neutrophil to lymphocyte ratio; CRP: C-reactive protein; LDH: Lactate dehydrogenase; PCT: Procalcitonin.

^*Based on Wilcoxon signed rank test.